NS002 — IND submission
Q3 2026
● NS002 Investigational New Drug ("IND") submission planned for the third quarter of 2026Source filing
NSRX biotech catalysts & pipeline
NASUS PHARMA LTD · Data as of 2026-09-08
Upcoming catalysts
NS002 — Topline data
Q1 2027
As we advance NS002 toward a pivotal trial in the fourth quarter of 2026 and topline data readout the first quarter of 2027, our strategic focus is increasingly centered on pre-commercial planning.Source filing